Literature DB >> 19745736

Contemporary assessment and management of congenital cholesteatoma.

Gresham T Richter1, Kenneth H Lee.   

Abstract

PURPOSE OF REVIEW: Only 2-4% of cholesteatomas presenting to pediatric otologists are congenital in origin. Disease severity can range from intratympanic pearls to middle ear and mastoid obliteration. Recently, highlighted variations of this rare disorder warrant a systematic approach to disease assessment and surgical decision making. This review provides a comprehensive method to diagnose and manage congenital cholesteatoma based on current literature. RECENT
FINDINGS: The holding theory of the origin of congenital cholesteatomas is that they arise from retained epithelial cell rest. Primary development can vary among sites within the middle ear and mastoid. 'Open' and 'closed' varieties have been proposed. However, disease severity depends on location, patient age, ossicular integrity, and number of anatomic sites involved. These variables have inspired the development of staging systems whereby appropriate surgical approaches can be designed. Computed tomography (CT) scans are necessary and continue to be the best radiographic tool for surgical planning. Over 30% of congenital cholesteatomas can be extirpated through a transcanal approach. Involvement of the posterior quadrant, over three anatomic subsites, or the mastoid cavity obligates standard canal wall-up techniques. Canal wall-down procedures are rarely required.
SUMMARY: Congenital cholesteatomas frequently extend beyond the typically described anterosuperior location of the middle ear. Ossicular destruction, mastoid infiltration, and tympanic membrane rupture are encountered more frequently than previously thought. Advanced disease predominately occurs in older children and requires sophisticated assessment and surgical planning beyond removing a simple keratin cyst.

Entities:  

Mesh:

Year:  2009        PMID: 19745736     DOI: 10.1097/MOO.0b013e3283303688

Source DB:  PubMed          Journal:  Curr Opin Otolaryngol Head Neck Surg        ISSN: 1068-9508            Impact factor:   2.064


  6 in total

1.  Stage progression of congenital cholesteatoma in children.

Authors:  Young Ho Kim; Jae Chul Yoo; Jun Ho Lee; Seung-Ha Oh; Sun O Chang; Ja-Won Koo; Chong Sun Kim
Journal:  Eur Arch Otorhinolaryngol       Date:  2011-09-06       Impact factor: 2.503

2.  [Current aspects of paediatric cholesteatomas].

Authors:  J P Thomas; S Volkenstein; A Minovi; S Dazert
Journal:  HNO       Date:  2013-05       Impact factor: 1.284

3.  Stem cells in middle ear cholesteatoma contribute to its pathogenesis.

Authors:  Julia Nagel; Saskia Wöllner; Matthias Schürmann; Viktoria Brotzmann; Janine Müller; Johannes Fw Greiner; Peter Goon; Barbara Kaltschmidt; Christian Kaltschmidt; Holger Sudhoff
Journal:  Sci Rep       Date:  2018-04-18       Impact factor: 4.379

4.  miR-199a Targeting PNRC1 to Promote Keratinocyte Proliferation and Invasion in Cholesteatoma.

Authors:  Lihui Yao; Wenjing Zhang; Jian Zheng; Xing Lu; Fan Zhang
Journal:  Biomed Res Int       Date:  2021-11-16       Impact factor: 3.411

5.  Congenital cholesteatoma presenting with Luc's abscess.

Authors:  Kalimuthu Santhi; Ing Ping Tang; Ahamad Nordin; Narayanan Prepageran
Journal:  J Surg Case Rep       Date:  2012-12-11

6.  Stem Cell-Induced Inflammation in Cholesteatoma is Inhibited by the TLR4 Antagonist LPS-RS.

Authors:  Matthias Schürmann; Johannes F W Greiner; Verena Volland-Thurn; Felix Oppel; Christian Kaltschmidt; Holger Sudhoff; Barbara Kaltschmidt
Journal:  Cells       Date:  2020-01-14       Impact factor: 6.600

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.